146 related articles for article (PubMed ID: 12130532)
21. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy.
Pardanani A; Ketterling RP; Brockman SR; Flynn HC; Paternoster SF; Shearer BM; Reeder TL; Li CY; Cross NC; Cools J; Gilliland DG; Dewald GW; Tefferi A
Blood; 2003 Nov; 102(9):3093-6. PubMed ID: 12842979
[TBL] [Abstract][Full Text] [Related]
22. PDGFRB disease: right diagnosis to prolong survival.
Passamonti F
Blood; 2014 Jun; 123(23):3526-8. PubMed ID: 24904095
[No Abstract] [Full Text] [Related]
23. Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFRA-positive chronic eosinophilic leukemia: implications for optimal dosing.
Klion AD; Robyn J; Maric I; Fu W; Schmid L; Lemery S; Noel P; Law MA; Hartsell M; Talar-Williams C; Fay MP; Dunbar CE; Nutman TB
Blood; 2007 Nov; 110(10):3552-6. PubMed ID: 17709602
[TBL] [Abstract][Full Text] [Related]
24. Growth-inhibitory effect of STI571 on cells transformed by the COL1A1/PDGFB rearrangement.
Greco A; Roccato E; Miranda C; Cleris L; Formelli F; Pierotti MA
Int J Cancer; 2001 May; 92(3):354-60. PubMed ID: 11291071
[TBL] [Abstract][Full Text] [Related]
25. Molecular response to imatinib mesylate following relapse after allogeneic SCT for CML.
McCann SR; Gately K; Conneally E; Lawler M
Blood; 2003 Feb; 101(3):1200-1. PubMed ID: 12529295
[No Abstract] [Full Text] [Related]
26. Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia.
Jovanovic JV; Score J; Waghorn K; Cilloni D; Gottardi E; Metzgeroth G; Erben P; Popp H; Walz C; Hochhaus A; Roche-Lestienne C; Preudhomme C; Solomon E; Apperley J; Rondoni M; Ottaviani E; Martinelli G; Brito-Babapulle F; Saglio G; Hehlmann R; Cross NC; Reiter A; Grimwade D
Blood; 2007 Jun; 109(11):4635-40. PubMed ID: 17299092
[TBL] [Abstract][Full Text] [Related]
27. Stable expression of small interfering RNA sensitizes TEL-PDGFbetaR to inhibition with imatinib or rapamycin.
Chen J; Wall NR; Kocher K; Duclos N; Fabbro D; Neuberg D; Griffin JD; Shi Y; Gilliland DG
J Clin Invest; 2004 Jun; 113(12):1784-91. PubMed ID: 15199413
[TBL] [Abstract][Full Text] [Related]
28. Stable molecular remission induced by imatinib mesylate (STI571) in a patient with CML lymphoid blast crisis relapsing after allogeneic stem cell transplantation.
Wassmann B; Scheuring U; Thiede C; Pfeifer H; Bornhäuser M; Griesinger F; Hochhaus A; Schleyer E; Gschaidmeier H; Hoelzer D; Ottmann OG
Bone Marrow Transplant; 2003 Apr; 31(7):611-4. PubMed ID: 12692630
[TBL] [Abstract][Full Text] [Related]
29. Platelet-derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcoma.
Kubo T; Piperdi S; Rosenblum J; Antonescu CR; Chen W; Kim HS; Huvos AG; Sowers R; Meyers PA; Healey JH; Gorlick R
Cancer; 2008 May; 112(10):2119-29. PubMed ID: 18338812
[TBL] [Abstract][Full Text] [Related]
30. Sustained cytogenetic remission induced by imatinib mesylate in a chronic myeloid leukemia patient who had a relapse into lymphoid crisis after allogeneic hematopoietic stem cell transplantation.
Yujiri T; Sato Y; Tanizawa Y
Int J Hematol; 2004 Jul; 80(1):67-9. PubMed ID: 15293571
[TBL] [Abstract][Full Text] [Related]
31. Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases.
Uehara H; Kim SJ; Karashima T; Shepherd DL; Fan D; Tsan R; Killion JJ; Logothetis C; Mathew P; Fidler IJ
J Natl Cancer Inst; 2003 Mar; 95(6):458-70. PubMed ID: 12644539
[TBL] [Abstract][Full Text] [Related]
32. Fusion of H4/D10S170 to PDGFRbeta in a patient with chronic myelomonocytic leukemia and long-term responsiveness to imatinib.
Drechsler M; Hildebrandt B; Kündgen A; Germing U; Royer-Pokora B
Ann Hematol; 2007 May; 86(5):353-4. PubMed ID: 17211520
[No Abstract] [Full Text] [Related]
33. The influence of imatinib mesylate (STI571) used alone or in combination with purine nucleoside analogues on the normal and chronic myelogenous leukaemia progenitor cells in vitro.
Korycka A; Robak T
Leuk Lymphoma; 2003 Sep; 44(9):1549-55. PubMed ID: 14565659
[TBL] [Abstract][Full Text] [Related]
34. Increased sensitivity to the platelet-derived growth factor (PDGF) receptor inhibitor STI571 in chemoresistant glioma cells is associated with enhanced PDGF-BB-mediated signaling and STI571-induced Akt inactivation.
Servidei T; Riccardi A; Sanguinetti M; Dominici C; Riccardi R
J Cell Physiol; 2006 Jul; 208(1):220-8. PubMed ID: 16575905
[TBL] [Abstract][Full Text] [Related]
35. Kinetics of BCR-ABL fusion transcript levels in chronic myeloid leukemia patients treated with STI571 measured by quantitative real-time polymerase chain reaction.
Stentoft J; Pallisgaard N; Kjeldsen E; Holm MS; Nielsen JL; Hokland P
Eur J Haematol; 2001; 67(5-6):302-8. PubMed ID: 11872078
[TBL] [Abstract][Full Text] [Related]
36. Complete and long-lasting cytologic and molecular remission of FIP1L1-PDGFRA-positive acute eosinophil myeloid leukaemia, treated with low-dose imatinib monotherapy.
Barraco D; Carobolante F; Candoni A; Simeone E; Piccaluga P; Tabanelli V; Fanin R
Eur J Haematol; 2014 Jun; 92(6):541-5. PubMed ID: 24460680
[TBL] [Abstract][Full Text] [Related]
37. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta.
Apperley JF; Gardembas M; Melo JV; Russell-Jones R; Bain BJ; Baxter EJ; Chase A; Chessells JM; Colombat M; Dearden CE; Dimitrijevic S; Mahon FX; Marin D; Nikolova Z; Olavarria E; Silberman S; Schultheis B; Cross NC; Goldman JM
N Engl J Med; 2002 Aug; 347(7):481-7. PubMed ID: 12181402
[TBL] [Abstract][Full Text] [Related]
38. Recurrent CEP85L-PDGFRB fusion in patient with t(5;6) and imatinib-responsive myeloproliferative neoplasm with eosinophilia.
Winkelmann N; Hidalgo-Curtis C; Waghorn K; Score J; Dickinson H; Jack A; Ali S; Cross NC
Leuk Lymphoma; 2013 Jul; 54(7):1527-31. PubMed ID: 23186533
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of platelet-derived growth factor receptor phosphorylation by STI571 (Gleevec) reduces growth and metastasis of human pancreatic carcinoma in an orthotopic nude mouse model.
Hwang RF; Yokoi K; Bucana CD; Tsan R; Killion JJ; Evans DB; Fidler IJ
Clin Cancer Res; 2003 Dec; 9(17):6534-44. PubMed ID: 14695158
[TBL] [Abstract][Full Text] [Related]
40. H4(D10S170), a gene frequently rearranged in papillary thyroid carcinoma, is fused to the platelet-derived growth factor receptor beta gene in atypical chronic myeloid leukemia with t(5;10)(q33;q22).
Schwaller J; Anastasiadou E; Cain D; Kutok J; Wojiski S; Williams IR; LaStarza R; Crescenzi B; Sternberg DW; Andreasson P; Schiavo R; Siena S; Mecucci C; Gilliland DG
Blood; 2001 Jun; 97(12):3910-8. PubMed ID: 11389034
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]